Digital Twins for Pharma

The pharmaceutical industry runs on a brutal economics of failure: a single drug candidate costs over $2 billion and a decade to bring to market, with a roughly 90% attrition rate across clinical development. Digital twins — virtual replicas of physical systems continuously synchronized with real-world data — are restructuring this equation at every stage, from the behavior of molecules in silico to the optimization of global cold-chain logistics. In pharma, the simulation-before-physical-intervention principle is not merely economically attractive; it is often the only ethical path, since the physical world contains living patients.

Manufacturing Intelligence: The Bioreactor as a Living Model

Biologics manufacturing — producing monoclonal antibodies, mRNA therapeutics, cell and gene therapies — is extraordinarily sensitive to process conditions. A 2°C temperature excursion in a 2,000-liter bioreactor can devastate an entire batch worth millions of dollars. Digital twins of bioprocesses ingest continuous sensor streams — dissolved oxygen, pH, agitation rate, cell viability, metabolite concentrations — and maintain a real-time mechanistic model of what is happening inside the vessel. This enables operators to intervene predictively rather than reactively, and to run "what-if" scenarios against the twin before touching the physical process.

Pfizer deployed process digital twins across its mRNA manufacturing network following the COVID-19 vaccine scale-up, dramatically compressing the time required to qualify new manufacturing sites from months to weeks by transferring validated virtual process models rather than relying solely on empirical runs at each site. Novo Nordisk has applied digital twins to its insulin fermentation processes at scale, reducing batch failure rates and enabling model-predictive control that continuously optimizes yield. Lonza and Samsung Biologics — two of the largest CMOs globally — have embedded digital twin platforms into their contract manufacturing offerings as a competitive differentiator, allowing clients to monitor their product's production in near real-time without being physically present.

The shift from batch to continuous manufacturing, accelerated by FDA encouragement under its Emerging Technology Program, makes digital twins structurally necessary rather than merely beneficial. A continuous process has no natural pause point for human inspection; the digital twin becomes the primary monitoring and control layer.

Drug Discovery: Simulating the Molecule Before Synthesizing It

At the earliest stages of the drug pipeline, digital twins operate at the molecular and cellular level. Physics-based molecular dynamics simulations, enhanced by AI-derived force fields, create virtual representations of protein targets and candidate molecules that can be screened computationally at scales utterly impossible in wet labs. Insilico Medicine used its generative AI and simulation platform to advance a novel fibrosis drug candidate from target identification to Phase II clinical trials in under four years — roughly half the industry average — with a fraction of the wet-lab synthesis required. Schrödinger's physics-based platform underpins computational campaigns at Pfizer, Bristol-Myers Squibb, and Takeda, replacing expensive high-throughput screening with ranked computational predictions that focus experimental resources on the most promising candidates.

NVIDIA's BioNeMo platform, launched as a cloud API in 2023 and significantly expanded through 2025, provides foundation models for protein structure prediction, molecular docking, and generative molecular design. It represents the infrastructure layer on which the next generation of molecular digital twins runs — GPU-accelerated, foundation-model-augmented simulation that makes exhaustive exploration of chemical space computationally tractable for the first time.

Virtual Patients and the Reinvention of Clinical Trials

Clinical trials are among the most expensive and logistically complex endeavors in all of industry. The randomized controlled trial, the gold standard for decades, requires enormous patient populations, years of follow-up, and exposes control-arm patients to placebo or standard-of-care when more effective treatments may be available. Digital twins of individual patients — computational models built from a patient's genomics, proteomics, imaging, EHR history, and real-world wearable data — are beginning to augment and in some cases replace human control arms.

Unlearn.AI has pioneered the regulatory pathway for "digital control arms," generating prognostic scores for individual trial patients that reduce the required size of placebo arms. Their approach has received endorsement from FDA and EMA, and has been applied in trials for ALS, multiple sclerosis, and Alzheimer's disease — conditions where denying effective treatment to a control-arm patient is ethically fraught. Roche has partnered with multiple computational modeling firms to run virtual patient cohorts for oncology trial design, allowing simulation of hundreds of protocol variations before committing to a single expensive physical trial design. The FDA's Complex Innovative Trial Design program explicitly encourages the use of modeling and simulation — effectively computational twins of trial populations — to support adaptive trial designs.

Certara, the largest biosimulation company in the industry, provides physiologically-based pharmacokinetic (PBPK) modeling used by the majority of top-20 pharma companies to predict how a drug will distribute, metabolize, and clear in human populations before first-in-human dosing. Their models are accepted by FDA and EMA as regulatory-grade submissions, establishing the precedent that a computational twin of human physiology can replace certain categories of physical experimentation for regulatory purposes.

Quality by Design and the Regulatory Frontier

The FDA's Quality by Design (QbD) framework asks manufacturers to understand their process deeply enough to predict quality outcomes from process parameters — a description that maps directly onto what a digital twin does. The FDA's Digital Health Center of Excellence and its Pharmaceutical Quality initiative have been explicitly encouraging digital twin adoption as a mechanism for enabling continuous manufacturing, real-time release testing, and post-approval process flexibility without requiring the traditional submission-and-approval cycle for each change.

In 2024 and 2025, the FDA issued draft guidance on the use of digital twins in drug manufacturing that established a framework for how process models can be validated and submitted as part of regulatory filings. This regulatory clarity — long awaited by the industry — has triggered significant investment. AstraZeneca, Eli Lilly, and Merck KGaA (EMD Serono) have each announced multi-year programs to build validated digital twin models for their key manufacturing processes, with the explicit goal of enabling model-informed real-time release that eliminates end-of-batch testing delays.

Personalized Medicine: The Patient-Specific Twin

The ultimate expression of digital twins in life sciences is a model specific to an individual patient — a computational representation of their unique physiology that can predict how they will respond to a given therapy, dose, or surgical intervention before it is administered. This vision is still partly aspirational but is advancing rapidly. Dassault Systèmes' Living Heart Project created a patient-specific cardiac digital twin used in FDA submissions for cardiac device approvals — a landmark in regulatory acceptance of personalized computational models. The project has since expanded to a Living Brain and Living Patient initiative. Siemens Healthineers has integrated patient-specific digital twins into its cardiac MRI workflow, enabling hemodynamic simulation from imaging data that guides interventional cardiology decisions. As multi-omic data becomes cheaper to acquire and AI becomes better at integrating heterogeneous biological data, the patient digital twin moves from academic proof-of-concept toward clinical standard of care.